📖 Newest epilepsy research on focal epilepsy, PTE, rare epilepsies, and more!
View this email in your browser ([link removed])
** The Latest Epilepsy Research
------------------------------------------------------------
CURE Epilepsy is dedicated to funding patient-focused research to find a cure for the 65 million people with epilepsy worldwide. This month, we share the following articles and abstracts which are furthering the study of epilepsy and bringing the world closer to a cure.
This issue of Epilepsy Research News includes summaries of articles on:
* New Method Developed for Triggering and Imaging Seizures in Epilepsy Patients ([link removed])
* Study Reveals Key Mechanisms of a Rare Form of Epilepsy ([link removed])
* Transcriptomic Alterations in Cortical Astrocytes Following the Development of Post-Traumatic Epilepsy (PTE) ([link removed])
* Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients ([link removed])
** New Method Developed for Triggering and Imaging Seizures in Epilepsy Patients
------------------------------------------------------------
*Featuring work from CURE Epilepsy Grantee Dr. Maxime O. Baud
Researchers have developed a new method for triggering and imaging seizures in epilepsy patients, offering physicians the ability to collect real-time data to tailor epilepsy surgery. The goal of epilepsy surgery is to remove the epileptic brain tissue and spare the healthy tissue to control seizures but avoid neurological deficits. Authors used stereotactic electroencephalography (sEEG) leads in targeted brain areas and an imaging approach called ictal SPECT to trigger and image patient-typical seizures.
Learn More ([link removed])
** Study Reveals Key Mechanisms of a Rare Form of Epilepsy
------------------------------------------------------------
*Featuring work by CURE Epilepsy Grantees, Drs. Edward Cooper and Jeffrey Noebels
New research is advancing the understanding of KCNQ2 encephalopathy. "KCNQ2 encephalopathy is a rare neurodevelopmental disorder caused by variants in the KCNQ2 gene, which provides the recipe for a type of brain potassium channel," explains lead author Timothy Abreo, a student in the Genetics and Genomics Graduate Program at Baylor College of Medicine, Houston, Texas, US. "The disorder usually manifests as seizures beginning within days after birth and developmental delays which are lifelong and without effective current treatment." Newly identified variants in the KCNQ2 gene are hard to assess because not every variant is disease-causing, and the reasons some variants lead to illness have been poorly understood.
Learn More ([link removed])
** Transcriptomic Alterations in Cortical Astrocytes Following the Development of Post-Traumatic Epilepsy (PTE)
------------------------------------------------------------
*Featuring work of CURE Epilepsy Grantees, Drs. Michelle Olsen and Michelle Theus
Traumatic brain injury (TBI) is one of the leading causes of disability and death worldwide, resulting from various accidents, sports-related injuries, and military combat situations. TBI can trigger long-term neurological complications, including PTE. Astrocytes, a type of glial cell in the brain, release pro-inflammatory molecules in response to brain injury and may contribute to the development of an epileptogenic environment in the brain.
Learn More ([link removed])
** Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
------------------------------------------------------------
Praxis Precision Medicines, Inc. provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients. The study used photo paroxysmal response (PPR) to stimulate seizure activity and measured changes in electroencephalogram (EEG) signatures as an indicator of anti-seizure efficacy of the potential new treatment for epilepsy. Patient EEG signatures were assessed at defined measurement points over a 24-hour period after receiving placebo or PRAX-628, and results were compared to baseline.
Learn More ([link removed])
** Check Out Our Latest:
------------------------------------------------------------
[link removed]
** Seizing Life Podcast ([link removed])
------------------------------------------------------------
[link removed]
** Epilepsy Explained Episode ([link removed])
------------------------------------------------------------
[link removed] [link removed] [link removed] [link removed] [link removed] [link removed]
[link removed]
Today's research has the ability to help
the 65 million people worldwide who are impacted by epilepsy every day.
And each one of those individuals has a story.
Read Desiree's story ([link removed])
[link removed]
Our mission is to find a cure for epilepsy, by promoting and funding patient-focused research.
CURE Epilepsy is a non-profit 501(c)(3) tax-exempt organization. Our tax identification number is 36-4253176.
Copyright (C) 2024 CURE Epilepsy. All rights reserved.
In the past you provided CURE Epilepsy your email address. Occasionally, you will receive updates from us about epilepsy research and news.
Our mailing address is:
CURE Epilepsy
420 Wabash Ave, Ste 650
Chicago, IL 60611
USA
Want to change how you receive these emails?
You can update your preferences ([link removed]) or unsubscribe ([link removed])
